

Open to Enrollment

Preventing Asthma in High Risk Kids (PARK)

Randomized, double-blind, placebo controlled, parallel arm study with 96 week treatment phase using Omalizumab or placebo and 96 week observation phase

Study Sponsor: The National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility: The child should be between 24-47 months of age with 2-4 episodes of wheezing in the past 12 months. At least one biological parent or sibling with history of asthma or allergy.

What is requested: Monthly injection of Omalizumab or placebo, nasal swabs, saliva, blood, skin testing, environmental samples, urine, and stool sample.

COVID19 Survey for Parents of Children with Food Allergy

Study Sponsor: Texas Children's Hospital/Baylor College of Medicine

Eligibility: Male or female, 18 years or older and the parent of at least one child diagnosed with food allergy.

What is requested: Survey completion

Outcome Measures for Eosinophilic Gastrointestinal Disease across Ages (CEGIR OMEGA)

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular and Patient-Reported Outcomes in Pediatric and Adult Patients with Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Eligibility: Male or female 3 years of age or greater diagnosed with EoE, EG or EC.

What is requested: Completion of questionnaires. Optional: a sample of tissue from your standard of care endoscopy and blood sample collection.

Regeneron Dupilumab EoE

A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis

Study Sponsor: Regeneron Pharmaceuticals

Eligibility: Male or Female 12 years of age or greater diagnosed with EoE as demonstrated by biopsy after 8 weeks of high dose PPI. Report of at least 4 episodes of dysphagia in the 2 weeks prior to baseline.

What is requested: Treatment with a shot of Dupilumab or Placebo, electronic diary completion, tissue sample from endoscopy procedure, and blood sample collection.

FARE patient registry

A registry for food-allergic individuals and their caregivers to quickly, conveniently and privately share their food allergy experiences through simple online surveys in order to help advance food allergy research.

Study Sponsor: Food Allergy Research and Education (FARE)

Eligibility: Male or female of all ages with food allergy

What is requested: Online survey completion

For more information, please contact

foodallergynurse@texaschildrens.org or 832-824-3398

Texas
Children's
Hospital
Food
Allergy
Program
Research
Studies



Food Allergy Program
at Texas Children's Hospital*



Texas Children's
Hospital

Upcoming Research Studies

EOE Kids

A randomized, 2-part double-blind, placebo-controlled study to investigate the efficacy and safety of Dupilumab in pediatric patients age 1 to <12 years with active eosinophilic esophagitis

Study Sponsor: Regeneron Pharmaceuticals

Expected start date: January 2021

Target enrollment: 3 patients

Eligibility: Male or female between the age of 1-12 years diagnosed with active eosinophilic esophagitis. History of symptoms to be a result of EOE such as abdominal pain, chest pain, acid reflux, food regurgitation, dysphagia, vomiting, or refusal to eat in the month prior to screening.

What is requested: Treatment with a shot of Dupilumab or Placebo, electronic diary completion, tissue sample from endoscopy procedure, and blood sample collection.

Dupilumab Eosinophilic Gastritis Study (CEGIR DEGAS)

A phase 2 randomized double-blind, placebo-controlled clinical trial to evaluate the efficacy of Dupilumab in subjects with eosinophilic gastritis

Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Expected start date: January 2021

Target enrollment: 3 patients

Eligibility: Male or female age 12 years and up with active eosinophilic gastritis as demonstrated by biopsy with a peak gastric count of ≥ 30 eos/hpf in at least 5 hpfs in the gastric antrum and/or body. History by patient report of moderate to severe EG symptoms (stomach pain, stomach cramping, nausea, bloating, burning feeling in the chest, starting to eat and feeling full too quickly, loss of appetite, vomiting, or diarrhea at least 2 days per week in the 2 weeks prior to screening.

What is requested: Treatment with a shot of Dupilumab or Placebo, electronic diary completion, tissue sample from endoscopy procedure, and blood sample collection.

Systems Biology of Early Atopy (SUNBEAM)

This is a prospective cohort study in which pregnant women (at any stage of pregnancy), the offspring's biological father, and the offspring will be enrolled and the offspring will be observed from birth to age 3 years.

Study Sponsor: The National Institute of Allergy and Infectious Diseases (NIAID)

Expected start date: January 2021

Target enrollment: 200 patients

Eligibility: Pregnant women age 18 years or older planning to give birth at the Texas Children's Hospital Pavilion for Women who agree to enroll offspring into the study at birth.

What is requested: Clinical assessments will be conducted, questionnaire information collected, and biological and environmental samples collected on the mother, father, and child in the prenatal, perinatal, and postnatal periods of the child's life.

For more information, please contact
foodallergynurse@texaschildrens.org or 832-824-3398

Texas
Children's
Hospital
Food
Allergy
Program
Research
Studies



Food Allergy Program
at Texas Children's Hospital*



Texas Children's
Hospital